{
    "2019-12-12": [
        [
            {
                "time": "2018-01-02",
                "original_text": "FDA Approves XELJANZ® XR (tofacitinib) Extended-Release Tablets for the Treatment of Ulcerative Colitis",
                "features": {
                    "keywords": [
                        "FDA",
                        "Approves",
                        "XELJANZ",
                        "tofacitinib",
                        "Ulcerative Colitis"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2018-01-03",
                "original_text": "Iterum Down as Sulopenem Antibiotic Fails in Phase III Study",
                "features": {
                    "keywords": [
                        "Iterum",
                        "Sulopenem",
                        "Antibiotic",
                        "Phase III",
                        "Fails"
                    ],
                    "sentiment_score": -0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-01-04",
                "original_text": "Big Pharma’s Coming Back in 2020. Don’t Hold Your Breath for Generic Drug Stocks",
                "features": {
                    "keywords": [
                        "Big Pharma",
                        "Generic Drug Stocks",
                        "2020"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "none",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}